Vertex Pharmaceuticals Inc (VRTX)
483.96
-10.65
(-2.15%)
USD |
NASDAQ |
Nov 14, 16:00
483.96
0.00 (0.00%)
After-Hours: 05:33
Vertex Pharmaceuticals Free Cash Flow (Quarterly): 1.302B for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 1.302B |
| June 30, 2024 | -3.830B |
| March 31, 2024 | 1.058B |
| December 31, 2023 | 118.50M |
| September 30, 2023 | 1.228B |
| June 30, 2023 | 1.075B |
| March 31, 2023 | 857.80M |
| December 31, 2022 | 1.045B |
| September 30, 2022 | 901.30M |
| June 30, 2022 | 1.086B |
| March 31, 2022 | 892.60M |
| December 31, 2021 | 933.20M |
| September 30, 2021 | 874.80M |
| June 30, 2021 | -249.60M |
| March 31, 2021 | 850.10M |
| December 31, 2020 | 443.84M |
| September 30, 2020 | 732.95M |
| June 30, 2020 | 1.021B |
| March 31, 2020 | 796.25M |
| December 31, 2019 | 429.27M |
| September 30, 2019 | 310.50M |
| June 30, 2019 | 447.39M |
| March 31, 2019 | 306.74M |
| December 31, 2018 | 298.93M |
| September 30, 2018 | 360.44M |
| Date | Value |
|---|---|
| June 30, 2018 | 292.09M |
| March 31, 2018 | 223.38M |
| December 31, 2017 | 184.53M |
| September 30, 2017 | -17.87M |
| June 30, 2017 | 164.28M |
| March 31, 2017 | 254.59M |
| December 31, 2016 | 129.94M |
| September 30, 2016 | 51.77M |
| June 30, 2016 | 24.94M |
| March 31, 2016 | -27.11M |
| December 31, 2015 | 16.62M |
| September 30, 2015 | -70.87M |
| June 30, 2015 | -123.69M |
| March 31, 2015 | -232.79M |
| December 31, 2014 | -196.46M |
| September 30, 2014 | -96.94M |
| June 30, 2014 | -139.62M |
| March 31, 2014 | -191.29M |
| December 31, 2013 | 5.288M |
| September 30, 2013 | -32.23M |
| June 30, 2013 | -2.728M |
| March 31, 2013 | -82.38M |
| December 31, 2012 | 12.51M |
| September 30, 2012 | 84.56M |
| June 30, 2012 | 102.86M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-3.830B
Minimum
Jun 2024
1.302B
Maximum
Sep 2024
578.28M
Average
883.70M
Median
Free Cash Flow (Quarterly) Benchmarks
| Eli Lilly and Co | -458.90M |
| Gilead Sciences Inc | 4.544B |
| Bristol-Myers Squibb Co | 5.267B |
| Moderna Inc | -1.717B |
| Sarepta Therapeutics Inc | -107.96M |